$40.58 million in sales expected for Aurora Cannabis Inc. (NYSE:ACB) this quarter

Analysts expect Aurora Cannabis Inc. (NYSE:ACB – Get Rating) to post revenue of $40.58 million for the current quarter, according to Zacks Investment Research. Four analysts provided earnings estimates for Aurora Cannabis, with the highest sales estimate at $42.80 million and the lowest estimate at $37.95 million. Aurora Cannabis recorded sales of $43.56 million in the same quarter last year, suggesting a negative year-over-year growth rate of 6.8%. The company is due to announce its next quarterly earnings report on Monday, January 1.

On average, analysts expect Aurora Cannabis to record annual sales of $179.38 million in the current fiscal year, with estimates ranging from $172.35 million to $186.16 million. . For the next fiscal year, analysts expect the company to post sales of $194.80 million, with estimates ranging from $177.88 million to $221.68 million. Zacks sales calculations are an average average based on a survey of research analysts who follow Aurora Cannabis.

Aurora Cannabis (NYSE:ACB – Get Rating) last released its quarterly results on Thursday, February 10. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.25). Aurora Cannabis had a negative net margin of 167.83% and a negative return on equity of 11.52%. The company posted revenue of $48.07 million in the quarter, compared to analyst estimates of $45.87 million.

(A d)

Some companies are expected to face major difficulties in this difficult market.

And you may own these stocks… But you should avoid them for now.

Discover the actions to avoid by clicking here.

Several equity research analysts have published reports on ACB shares. Zacks Investment Research upgraded Aurora Cannabis from a “sell” rating to a “hold” rating in a Monday, January 31 research note. Cantor Fitzgerald reduced his target price on Aurora Cannabis from CA$10.75 to CA$7.60 in a Friday, February 11 research note. Finally, CIBC reduced its target price on Aurora Cannabis from CA$9.25 to CA$6.50 in a Thursday, February 3, research note. Three equity research analysts gave the stock a sell rating and eight issued a hold rating for the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $6.98.

NYSE: ACB opened at $3.54 on Friday. Aurora Cannabis has a 1-year low of $2.89 and a 1-year high of $10.64. The company has a debt ratio of 0.19, a quick ratio of 3.70 and a current ratio of 4.92. The stock has a market capitalization of $760.30 million, a PE ratio of -2.25 and a beta of 2.91. The stock has a 50-day moving average price of $3.81 and a 200-day moving average price of $5.39.

Several institutional investors and hedge funds have recently increased or reduced their stake in the company. City State Bank bought a new position in Aurora Cannabis stock during the fourth quarter for a value of $64,000. Merlin Capital LLC purchased a new position in Aurora Cannabis stock during the fourth quarter for a value of $2,110,000. Wells Fargo & Company MN increased its position in Aurora Cannabis stocks by 99.4% during the fourth quarter. Wells Fargo & Company MN now owns 12,158 shares of the company worth $66,000 after purchasing an additional 6,060 shares during the period. WMS Partners LLC purchased a new position in Aurora Cannabis stock during the fourth quarter for a value of $114,000. Finally, Toroso Investments LLC increased its position in Aurora Cannabis shares by 124.3% during the fourth quarter. Toroso Investments LLC now owns 53,935 shares of the company worth $292,000 after purchasing an additional 29,884 shares during the period. Institutional investors and hedge funds own 17.61% of the company’s shares.

Aurora Cannabis Company Profile (Get an evaluation)

Aurora Cannabis Inc produces, distributes and sells cannabis and cannabis-derived products in Canada and abroad. It is also involved in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale and retail distribution. The company produces various strains of dried cannabis, cannabis oil and capsules, as well as topical kits for medical patients.

Read more

Get a Free Copy of Zacks’ Aurora Cannabis (ACB) Research Report

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Earnings history and estimates for Aurora Cannabis (NYSE:ACB)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Aurora Cannabis right now?

Before you consider Aurora Cannabis, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market hits…and Aurora Cannabis didn’t make the list.

While Aurora Cannabis currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Sallie R. Loera